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Abstract 
We have found a common structural motif in human autoantigens, heat shock proteins and viral proteins. Peptides modelled after 
sequences present in those molecules were synthesized and immunomodulating properties tested. They share a core of 15 amino acid 
residues and a common pattern ('2-6-1 l '  motif) characterized by requirements at fixed positions with respect o a Pro (position 6); an 
apolar residue or a Lys at position 2; and a Glu, Asp or Lys at position 11. Any of these peptides, when added to cultures of 
lymphomononuclear cells, caused the activation of monocytes manifested by a release of IL-1 a, IL-1/3 and TNFa. A release of INF',/ 
and IL-2 took also place; this release was abolished by anti-DR antibodies. Neither IL-4 nor IL-5 could be detected. This suggests a 
presentation by APCs and the appearance of cells with a Thl phenotype. Monocytes and Thl cells freshly obtained from 12 patients of 
Graves' disease, 8 of Hashimoto's disease and 8 of primary biliary cirrhosis exhibited activation features imilar to those found in cells 
from healthy subjects incubated in the presence of peptides with a '2-6-11' motif and representing fragments of autoantigens. Their 
immunopotentiating properties uggest heir involvement in the initiation or progression of the autoimmune response mediated by 
activated monocytes and Th 1 cells. 
Keywords: Autoantigen; Cytokine; Monocyte; Thl; APC; Autoimmune disease 
1. Introduction 
The presence of autoantibodies against specific 'self' 
structures is characteristic of autoimmune diseases. How- 
ever, their involvement in the pathogenesis of the disease 
usually depends on the localization of the presumptive 
target antigen (reviewed in [1]). Autoantigens processed 
and presented by professional or nonprofessional APCs 
could lead to the activation of T helpers favoring in this 
way the initiation, or the progression, of an autoimmune 
attack. It is not infrequent o find macrophages and lym- 
phocytes infiltrating target issues in organ specific autoim- 
mune diseases. The molecular mimicry between microbial 
or viral peptides and self peptides presented by APCs 
Abbreviations: Graves' disease (GD); Hashimoto's disease (HD); 
Primary biliary cirrhosis (PBC); Healthy subject (HS); S. aureus protein 
A (SPA); Antigen presenting cell (APC); Heat shock protein (hsps); 
Phytohemagglutinin (PHA) 
* Corresponding author. Fax: + 34 48 425649. 
would explain that an infection is often associated with the 
onset of an autoimmune attack (reviewed in [2]). A similar 
mimicry between heat shock proteins (hsps) and certain 
autoantigens has been linked to their possible involvement 
in some human autoimmune diseases (reviewed in [3]). In 
a recent review Elson et al. [4] propose that organ-specific 
autoimmune diseases result from the stimulation of im- 
munologically ignorant T cells; they suggest hat cytokines 
associated with T helper 1 cells alter the processing pattern 
of antigens and that the novel peptides so produced, and 
not previously exposed by thymic dendritic cells, are pre- 
sented leading to an activation of autoreactive T cells. The 
recruitment of nonprofessional APCs, such as macrophages, 
that have the processing machinery able to generate new 
antigen cleavage patterns, is another mechanism to pro- 
duce peptides capable of triggering an autoimmune re- 
sponse. 
The aim of this study was to investigate the possible 
existence of a common structural pattern in autoantigens 
capable of conferring immunopotentiating properties to 
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Table 1 
'2-6-11' motif in human autoantigens 
Autoantigens Ref. Disease PI * Sequence Position 
Mitochondrial M2 [3] Primary biliary cirrhosis P1 AKILVPEGTRDVPL 241-254 
P2 FADYRPTEVTDLKP 270-283P2 
Glycogen phosphorylase(M4) [2] Primary biliary cirrhosis P3 ALERWPVHLLETLL 384-397 
P4 KVHINPNSLFDIQV 555-568 
17a-hydroxylase [3] Addison's disease P5 WLKIFPNKTLEKLK 220-233 
P6 NGNAGPDQDSELLS 275-288 
TSH receptor [ 1 ] Graves' disease P7 SVTALPSKGLEHLK 237-250 
Thyroglobulin [3] Thyroid disease P8 QVDAQPLRPCELQR 24-37 
Thyroid peroxidase [24] Hashimoto's thyroiditis P9 CLCADPYELGDDGR 823-836 
H +, K + ATPase [24] Autoimmmune gastritis P10 GVTLRPDVYGERGL 81-94 
P 11 SGLVDPSFGFEEGK 163 - 176 
P 12 LKDMDPSELVEALR 679-692 
Glutamic Acid Decarboxylase [3] Insulin-dependent diabetes P13 GVPDSPQRREKLHK 506-519 
Insulin receptor [2] Insulin-dependent diabetes P14 LLRWEPYWPPDFRD 476-489 (a) 
P 15 SARTMPEAKADDIV 89-102 (b) 
P 16 GYLDQPDNCPERVT 491-504 (b) 
Islet cell Agsi 2 [25] Insulin-dependent diabetes PI7 YINASPIIEHDPRM 373-386 
Carboxypeptidase [26] Insulin-dependent diabetes P 18 RIHIMPSLNPDGFE 109-122 
P 19 AVPYSPAAGVDFEL 385 -398 
Asialoglycoprotein receptor H1 [2] Chronic active hepatitis P20 FKNWRPEQPDDWYG 234-247 
o~-Collagen II [ 1 ] Rheumatoid arthritis (RA) P21 GANGEPGKAGEKGL 540-553 
P22 GLRGLPGKDGETGA 558-571 
P23 GARGAPGERGETGP 747 -760 
P24 GIVGLPGQRGERGF 912-925 
KU (p70/p80) [3] Scleroderma P25 GSDIVPFSKVDEEQ 317-330 
snRNP U1 [3] Systemic lupus erythematosus P26 LGPDGPDGPEEKGR 335-348 
(SEE) 
Sm-D autoantigen [ 1 ] SLE P27 LVDVEPKVKSKKRE 80-94 
Acetyl choline receptor [3] Myasthenia gravis P28 DLVGIPGKRSERFY 203-216 
P29 LVFLLPADSGEKIS 296-309 
LHCG receptor and LH receptor [24] Premature ovarian failure P30 KLQALPSYGLESIQ 232-245 
Histidyl-tRNA synthetase [ 1 ] Myositis P31 EVIDTPVFELKETL 91-1 04 
Isoleucyl-tRNA synthetase [ 1 ] Myositis 
Myeloperoxidase [27] Glomerulonephritis 
Serine protease [ 1] Wegener' s granulomatosis 
C 1 -inhibit°r [ 1 ] Angioedema 
IL- I  ot [28] Schnitzler's syndrome, 
[291 RA 
Glutamic acid decarboxylase-2 [30] Stiff-man syndrome 
P32 VLLQTPAQEGEEPW 239-252 
P33 ILERFPGAYLKGKK 275-288 
P34 VVHQAPYFGAEDYR 329-332 
P35 YLINSPVVRAENLR 626-629 
P36 KYLIDPVSVQDKDT 785-798 
P37 VIHQDPEALKDIKS 852-865 
P38 SLWRRPFNVTDVLT 132-145 
P39 FVRWLPAEYEDGFS 183-196 
P40 LKSLNPRWDGERLY 362-375 
P41 PLVLGPTAMRKYLP 396-409 
P42 IKEFIPFSGFKSGT 70-83 
P43 SVEKVPMMNSKKYP 296-309 
P44 CLAGGPPSITDFQI 243-256 
Oligodendrocyte-myelin [31 ] Multiple sclerosis 
glycoprotein precursor 
Myelin-associated glycoprotein [29] Multiple sclerosis 
precursor 
hsp60 [32] Rheumatoid arthritis 
hsp70 [3] SLE 
hsp90 [2] Ankylosing spondylitis and SLE 
64 kDa protein [33] Autoimmune ophthalmopathy 
P45 ELADQPQNLEEILM 158-171 
P46 EIIGWPGGSGDGIF 202-215 
P47 NLSTLPSGLQENII 45 - 58 
P48 LSNVSPELGGKYYF 104-117 
P49 VSCMVPDNCPELRP 157-170 
P50 KKQSKPVTTPEEIA 155-168 
P51 VVTEIPKEEKDPGM 543-557 
P52 RKFGDPVVQSDMKH 76-89 
P53 AVITVPAYFNDSQR 142-155 
P54 EGLELPEDEEEKKK 539-552 
P55 KKALGPRRNSDLGK 83 -96 
P56 VKKNEPLMEKEAKD 243 -256 
P57 SIFDEPLERVKNND 289-301 
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Table 1 (continued) 
Autoantigens Ref. Disease PI * Sequence Position 
Amphiphysin [34] Stiff-man syndrome P58 SVVIEPASNHEEEG 542-555 
TIGAEPKETTEDAA 560-573 
Laminin B2 chain [35] Good pasture'syndrome P59 LGKTLPCGLTKTYT 303-316 
P60 PVSGAPAPWVEQCI 370-383 
P61 HLMDQPLSVDEEGL 1107-1120 
N-cadherin [36] Pemphigus P62 KLSLKPTKTEESVK 120-133 
P63 TKLSDPANWLKIDP 535-549 
P64 SAAPHPGDIGDFIN 824-838 
E-cadherin [36] Pemphigus P65 LLLRSPLGSQERSE 13 -23 
P66 HVHGAPAPPEKRPR 35 -49 
P67 ILSQDPELPDKNMF 300-314 
P68 PIFVPPEKRVEVSE 480-493 
P69 SIILKPKMALEVGD 645 -659 
P70 AVVKEPLLPPEDDT 731-745 
SS-B/La [37] SLE P71 PSKPLPEVTDEYKN 93 - 106 
Ro /SS-A  [37] SLE, Sjogren's yndrome P72 LAVAEPAVYFKEQF 14-27 
P73 TLIVRPDNTYEVKI 173-186 
P74 PVIQNPEYKGEWKP 264-277 
FcRII and FcRIII IgG [38] SLE, Sjogren' s and syndrome P75 QAAAPPKAVLKLEP 1 - 14 
systemic sclerosis 
RNA polymerase [39] Scleroderma, SLE 
Laminin B [40] SLE, RA, and polymyalgia 
rheumetica 
Viral protein hepatitis B
virus DNA polymerase 
P76 FIAEVPIIAIDWVQ 28-51 
P77 RLGLIPLISDDIVD 67 -80 
P78 QAPYDPNGKPERFY 216-229 
P79 FKTTIPEEEEEEEE 546-559 
Pv I PLGFFPDHQLDPAS 10-23(CI) 
Pv2 TVELLPYLPSDFFL 11-24 (E) 
Pv3 LVDKNPHNTAESRL 363-376 (E) 
Pv4 IVAPLPIHTAELLA 707-720 (E) 
* PI, Peptide identification. 
potential fragments. Among the properties considered we 
focused on the activation of monocytes and T helper cells 
with a Thl phenotype. 
We have already reported the immunomodulating prop- 
erties of a series of peptides with sequences present in S. 
aureus protein A (SPA), and extracellular matrix proteins. 
These peptides hare a core of fifteen amino acid residues 
with a common structural pattern ('2-6-11' motif) consist- 
ing basically in the presence of certain amino acid residues 
at fixed positions with respect o a Pro (position 6); an 
apolar residue or a Lys at position 2; and a Glu, Asp or 
Lys at position 11. Any of these peptides, when added to 
cultures of human lymphomononuclear cells, were capable 
of activating monocytes [5,6]. More recently, we have also 
found that peptides with this pattern are presented by 
HLA-II inducing the differentiation of CD4 ÷ T cells to- 
wards a Thl functional phenotype [7]. We report now the 
existence of this structural '2-6-11' motif in autoantigens, 
viral and heat shock proteins permitting them to be pre- 
sented by APCs, thus triggering an immune response 
mediated by T cells with a Thl phenotype; this could 
explain, at least in part, the attack against 'self' which 
takes place in autoimmune diseases. This idea received a
further support after the observation here reported that 
patients of several autoimmune diseases have monocytes 
and Thl cells in a state of activation similar to that 
induced by fragments of autoantigens with the '2-6-11' 
motif on a population of lymphomononuclear cells ob- 
tained from healthy individuals. 
2. Material and methods 
2.1. Peptide synthesis 
Peptides were synthesized by the solid phase method as 
described [8] with the Fmoc modification [9]. 
2.2. Cell source and preparations 
Lymphomononuclear cells were obtained from hep- 
arinized blood of volunteers, healthy subjects or patients, 
by centrifugation over Ficoll-Hypaque as reported in the 
literature [10]. 
2.3. Cell culture conditions 
Cultures contained 10 6 cells per ml and peptide concen- 
tration was 30 /xg/ml in RPMI-1640 medium (Biochrom, 
Berlin, Germany) supplemented with 10% autologous 
serum, 2 mM L-glutamine, penicillin (100 U/ml)  and 
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streptomycin (100 /xg/ml) in humidified atmosphere with 
5% CO 2 at 37°C. 
2.4. Anti-HLA-DR antibody 
Anti-HLA-DR antibody was obtained as described in 
the literature [11]. 
2.5. Cytokine determination 
Cytokine determination was carried out in culture su- 
pernatants by the quantitative sandwich enzyme im- 
munoassay technique with commercially available kits 
(Genzyme, Cambridge, MA). For the determination f the 
different cytokines lymphomononuclear cells were placed 
on 16 mm diameter wells (2 X 10 6 cells/ml in each well). 
Peptides were added to give a ratio of 30 /~g/106 cells. 
After the incubation period plates were centrifuged and the 
determination of the different cytokines carried in dupli- 
cates using I00 /zl of the supernatant of each well; the 
sensitivity of these assays was 50 pg/ml for each cy- 
tokine. Whenever IL-2 had to be determined, specific 
antibody against its receptor (anti-h-rlL-2 Ab BT563, 
Biotest Pharma, Germany) was added to the medium (2.5 
/~g/106 cells) at the beginning of a 7-day incubation 
period, in order to avoid that binding of IL-2 to its soluble 
receptor could mask its release. When the incubation was 
carried out in the presence of anti-HLA-DR antibody, this 
was added to the wells after the cells to give a final 
concentration of 2.5 /xg/ml. After 5 minutes the peptide 
was added. 
2.6. TNFot and IFNT gene expression. 
For the preparation of RNA 20 X 10 6 lymphomononu- 
clear cells obtained from healthy individuals were incu- 
bated for different periods in the presence of active pep- 
tides. Non-adherent cells were collected and centrifuged; 
pelleted cells were immediately disrupted in 4 M guani- 
dinium thiocyanate, 25 mM Na 3 citrate, 0.2% sarkosyl, 2 
mM 2-mercaptoethanol s ution. Total RNA from each 
sample was pelleted by ultracentrifugation ver a cesium 
chloride gradient (5.7 CsC1, 100 mM EDTA) for 22 h. The 
pellet was precipitated with absolute ethanol and resus- 
pended in water. For cDNA synthesis Eppendorfs contain- 
ing 2 /zg of RNA were incubated for 5 min at 90°C and 
chilled on ice for 3 min. Samples were then incubated for 
1 h at 37°C after adding 10 U of RNAsin, 1 mM deoxynu- 
cleoside triphosphates, 100 U M-MLV reverse transcrip- 
tase (Gibco BRL, UK), 100 pmol of hexamers as primers 
and 8 /zl of reverse transcriptase buffer; final volume was 
20 /zl. After the incubation, reaction was heat-inactivated 
at 90°C for 5 min, and cDNA frozen at -20°C until use. 
The polymerase chain reaction (PCR) was carried out in an 
automatic CNA thermal cycler. The reaction mixture con- 
tained 5 /zl of the isolated cDNA, 30 pmol of sense and 
antisense primer, 1 mM deoxynucleotide triphosphates and 
0.25 U Taq DNA polymerase (Promega, Madison WI, 
USA) in a final volume of 100 /zl. The cycle program was 
set to denature at 95°C for 1 min, to anneal at 52°C for 30 
s and to extend at 72°C for 30 s for a total of 35 cycles. 
Electrophoresis of the PCR products was performed on 
1.5% agarose gels containing 1 /zg/ml ethidium bromide. 
As molecular weight markers A and ~bx-100 were used. 
Primers were prepared with an Applied Biosystem 391 
synthesizer, using published gene sequences. 
2. 7. Surface marker CD14 
Immunofluorescence determination of CD14 was per- 
formed with a Coulter Epics flow cytometer using the 
monoclonal antibody Leu-M3 obtained from Becton-Dick- 
inson (Mountain View, CA) as a conjugate of fluorescein 
isothiocyanate (FITC) under conditions already specified 
(6) 
2.8. Statistical analysis 
Data were analyzed by the ANOVA and Fisher's PlsD 
tests; a p value less than 0.05 was considered to be 
significant. 
3. Results 
3.1. '2-6-11' motif in autoantigens 
Upon examining the structures of autoantigens, heat 
shock proteins and hepatitis B virus DNA polymerase we 
have found that a '2-6-11' motif is present in their se- 
quences at least once as shown in Table 1. Peptides 
containing fifteen amino acid residues (14 of them repre- 
senting sequences corresponding to the '2-6-11' motif and 
an extra valine at the C end) were synthesized in order to 
investigate their potential immunomodulating properties. 
3.2. Cytokine release by lymphomononuclear from healthy 
subjects 
Cytokines released to the medium were determined 
after incubating human lymphomononuclear cells in the 
presence of synthetic peptides corresponding to fragments 
of autoantigens, hsps and viral DNA polymerase and con- 
taining the '2-6-11' motif. Two peptides were used as 
positive controls and known from previous work to have 
immunomodulating properties [5,6]: NVLGAPKKL- 
NESQAV (Pal) not present in natural proteins, and pep- 
tide QVLASPGSCLDEFRV (Pa2) from a 1 collagen. As 
negative controls several peptides lacking that motif were 
used: ADAQQNKFNKDQQSV (Pcl) from SpA; a second 
one with a sequence present in thyroglobulin, SGLYN- 
PIVFSASGAV (Pc2), in TSH receptor, EELKN- 
PQEETLQAFV (Pc3), and in hsp 60 SKGANPVIR- 
RGVMLV (Pc4). In all these peptides the valine residue at 
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the C-end was added for convenience of the synthesis and 
it is not necessarily present in the sequence of the refer- 
ence protein. We have tested a number of peptides using 
cells obtained from 18 different healthy individuals. 
Fig. 1 shows the release of TNFc~, IL-1/3 and IL-1 a 
induced by the different peptides when lymphomononu- 
clear cells were incubated in their presence at the end of a 
24 h period. All  of the peptides having the '2-6-11' motif 
induced a considerable release of these cytokines, thus 
reflecting their ability to activate monocytes. It may be 
seen a that a serine residue at position 2, or that of an 
aspartic acid at position 11 resulted in peptides with 
relatively low activity when tested with cells belonging to 
healthy individuals. 
Fig. 2 shows the release of IFNy and IL-2 induced by 
the different peptides, in the absence or presence of anti-DR 
antibodies, on lymphomononuclear cells belonging to 5oo  
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Fig. 2. Release of IFNy (A) and IL-2 (B) by lymphomononuclear cells 
obtained from healthy subjects induced by immunomodulating peptides. 
Values represent the mean of duplicates of 15 independent experiments 
using cells obtained from the blood of different individuals. Differences 
between cells treated with immunomodulating peptides and cells treated 
with negative control peptides (Pcl, Pc2, Pc3, Pc4) or in the absence of 
peptides were statistically significant (P < 0.001). Peptide concentration 
was always 30 /zg/ml. The incubation time was 24 h for IFNT and 7 
days for IL-2. (C) Effect of anti-HLA-DR antibody on IL-2 release 
induced by active peptides. The values represent the mean of 3 indepen- 
dent experiments. The concentration f antibody was 2.5 /zg/ml. 
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Fig. 1. Monocytic ytokines released by lymphomononuclear cells from 
healthy subjects after peptide activation. Results represent the mean of 
duplicates of 18 independent experiments u ing cells obtained from the 
blood of diferent healthy individuals. Differences between cells treated 
with immunomodulating peptides and cells treated with negative control 
peptides (Pcl, Pc2, Pc3, Pc4) or in the absence of peptides were 
statistically significant (P < 0.001). Peptide concentration was always 30 
/xg/ml. The incubation time was 24 h. 
healthy individuals. Both cytokines were released in 
amounts higher than those induced by negative control 
peptides or in the absence of any added peptides. The 
possible release of IL-4 and IL-5 to the medium was 
investigated, but its presence was never detected when 
lymphomononuclear cells obtained from healthy subjects 
were incubated for 24 h under conditions identical to those 
used in the determination of IFNy. As positive controls for 
the release of IL-4 and IL-5 phytohemagglutinin was used 
(data not shown). These results are indicative of a selective 
induction of T helper cells with a Thl phenotype. Fig. 2 
shows also that the release of IL-2 was blocked when an 
anti-DR antibody was present in the medium. A tentative 
interpretation of these results could be that active peptides 
might be presented, probably by monocytes, to T helpers. 
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3.3. Expression of TNFt~ and IFNT genes 
We analyzed TNFc~ gene expression induced by im- 
munopotentiating peptides searching its corresponding 
mRNA. After 3 h of incubation total RNA was isolated 
from lymphomononuclear cultures treated with peptide P8, 
Pal, or, as negative controls, from cultures to which no 
peptides were added. The corresponding cDNA was ob- 
tained and used in the PCR experiments employing primers 
synthesized according to the published sequence for the 
TNFa gene [41]. The sequence of the sense was 5'- 
GTCAGATCATCTTCTCGAACC-3', and that of the anti- 
sense 5'-CAGATAGATGGGCTCATACC-3'. 
Amplified sequence corresponds to positions from 381 
to 740 within the mRNA of TNFc~. When cells were 
incubated for three h in the presence of either of the two 
active peptides indicated above, a clear band appeared on 
the gel corresponding to a cDNA of 360 bp showing that 
the expression of the TNFc~ gene had been induced. When 
RNA was extracted from cells incubated under the same 
conditions, but in the absence of active peptides, the 
equivalent band of cDNA was very weak, almost imper- 
ceptible. 
INFy gene expression was also investigated. After 6 h 
of incubation total RNA was isolated from lym- 
phomononuclear cultures treated with peptides P8 or Pal. 
For the PCR experiments primers were synthesized (sense, 
5'-ATCGTTTTGGGTTCTCTTGG-3'. and antisense: 5'- 
TCTTqq'GGATGCTCTGGTCA-3') based on the pub- 
lished sequence of the INFy gene [42], and amplifying a 
235 bp fragment of the IFNy cDNA. We found bands of 
60O 
11111 
5O 
E 
I L -2  =so 
2OO 
_ 150 
E 
i 11111 
50 
0 HS GD PI~ HD 
Fig. 3. Spontaneous release of cytokines by lymphomononuclear cells 
obtained from patients of autoimmune diseases. Values represent he 
mean of duplicates of independent experiments using blood from 7 
patients of Graves' disease (GD), 4 patients of Hashimoto's disease (HD) 
and 4 of primary biliary cirrhosis (PBC). The differences between cells 
obtained from patients and healthy subjects (HS) were statistically signifi- 
cant (P  < 0.001). At the moment of the blood extraction the patients 
selected for these experiments had a high percentage of activated mono- 
cytes (CD14 + > 20%). 
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Fig. 4. Release of monocytic ytokines by lymphomononuclear cells from 
patients induced by specific immunopotentiating peptides. The patients 
selected for these determinations (5 of GD, 4 of HD and 4 of PBC) had at 
the moment of the blood extraction a percentage of cells expressing 
CD14 between 10 and 15. Experimental conditions were the same as in 
Figs. 4 and 1. The differences between cells treated with active peptides 
and control peptides or in the absence pf peptides were statistically 
significant (P  < 0.00t). 
this length on gels corresponding to cultures treated with 
actives peptides, whereas no bands of amplification was 
observed in control cultures. Since the fragment of the 
INFy gene chosen for amplification contains in its ge- 
nomic version an intron of 1300 bp the possibility that the 
amplified band could correspond to contaminating e- 
nomic DNA is easily discarded. 
3.4. Cytokine release by lymphomononuclear cells belong- 
ing to patients of autoimmune diseases 
We have also studied the spontaneous release of cy- 
tokines when lymphomononuclear cells obtained from pa- 
tients of autoimmune diseases were incubated in the ab- 
sence of immunomodulating peptides. Fig. 3 shows the 
spontaneous release of cytokines TNFa, IL-1/3, IL-2 and 
IFNT by lymphomononuclear cells from patients of GD, 
HD and PBC. All the patients included in this study had at 
the moment of the extraction a high percentage of acti- 
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vated monocytes (CD14÷> 20), i.e. a value much higher 
than the average found in healthy subjects (CD14÷< 10). 
Lymphomononuclear cells from all the patients studied 
released to the incubation medium the four cytokines 
tested in amounts considerably higher than those released 
by cells belonging to healthy individuals. It is also worth 
noting that the amount of the cytokines released by cells 
belonging to patients was similar to that released by cells 
obtained from healthy individuals, if incubations of the 
latter were carried out in the presence of immunopotentiat- 
ing peptides containing a '2-6-11' motif. In no case IL-4 
could be detected in the medium. These cells released this 
cytokine when incubated in the presence of phytohemag- 
glutinin (data not shown). 
Fig. 5 show the release of cytokines by the lym- 
phomononuclear population belonging to patients of GD, 
HD or PBC, when incubations were carried out in the 
presence of one of the active peptides including that 
related to the autoantigen corresponding to each disease. 
All the patients selected for this experiment showed an 
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Fig. 5. Release of IFN7 and IL-2 by lymphomononuclear cells from 
patients induced by specific immunopotentiating peptides. The patients 
selected for these experiments were the same as those selected for the 
experiments ummarized in Fig. 4. Experimental conditions were the 
same as in Fig. 2. The differences between cells treated with active 
peptides and control peptides or in the absence ofpeptides were statisti- 
cally significant (P < 0.001). 
expression of CD14 in approx. 15% of the cells of the 
entire lymphomononuclear population. It may be seen that 
active peptides timulated the release of cytokines TNFa, 
IL-1/3, (Fig. 4), IL-2 and IFN7 (Fig. 5). When a peptide 
related to the autoantigen characteristic of GD, PBC or HD 
matched the lymphomonuclear cells belonging to patients 
of the corresponding autoimmune disease, the amounts of 
cytokines released were higher than those obtained with 
other active peptides. 
In order to check that the higher spontaneous cytokine 
release by the cells obtained from patients was not due to 
the lysis of these cells, but to a higher cytokine production, 
we carried out the determination of cytokines released to 
the medium and then after the complete disruption of the 
cells. Lymphomononuclear cells freshly obtained from 
healthy subjects were resuspended in the incubation 
medium and disrupted in a nitrogen bomb. Neither TNFa 
nor IFNy were detected. However, TNFa and IFNT were 
detected when an equivalent number of cells obtained from 
a patient and treated under the same condition. Lym- 
phomononuclear cells from healthy subjects were incu- 
bated for 24 h in the presence of active peptides Pal and 
P8. Both IFN7 and TNFa were released to the medium. 
Neither of these two cytokines were detected after remov- 
ing the medium and disrupting the cells with a nitrogen 
bomb. Moreover, when cells from a patient with GD were 
incubated in the absence of immunopotentiating peptides 
for 24 h cytokines were released to the medium, and only 
negligible amounts of cytokines could be detected after 
removing the medium and replacing it with fresh medium 
and disrupting the cells. We have also studied the release 
of IL-4 and IL-5 to the medium and their possible reten- 
tion by the cells after incubating them for 24 h in the 
presence of PHA. The amount of the cytokines retained by 
the cells was below 10% of the amount released. 
4. Discussion 
The striking presence of amino acid sequences enclos- 
ing a '2-6-11' motif in the autoantigens studied suggests 
that a presentation of fragments of them with sequences of 
this type could play a key role in the autoimmune re- 
sponse. A random search of unrelated human proteins 
permits us to assert that this structural pattern is not as 
universal as it might be thought, since many of them lack 
this motif altogether. Furthermore, for a protein to behave 
as an autoantigen or an immunopotentiating agent in au- 
toimmunity, the presence of a specific motif or sequence 
would not be the sole prerequisite. The protein would also 
have to be processed in a way that at least one of the 
resulting peptides with the indicated motif could be pre- 
sented by an APC, professional or nonprofessional. 
We have also included in Table 1 three peptides with a 
serine residue at position 2: peptide P25, derived from KU 
(p70/p80) and peptides P48 and P49 from myelin-associ- 
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ated glycoprotein precursor. We propose this new variant 
of the '2-6-11' motif, since peptides of this type have also 
proved to be slightly active (Figs. 1 and 2). 
As shown in Figs. 1 and 2 peptides having the active 
motif (fragments of autoantigens, viral and heat shock 
proteins) elicited a response consistent with a stimulation 
of monocytes and a presentation leading to a differentia- 
tion of T helpers towards a Thl phenotype. Lym- 
phomononuclear cells from patients of GD, HD or PBC 
spontaneously, i.e. without he addition of immunopotenti- 
ating peptides, released cytokines indicating an activation 
of monocytes and the presence of T helper cells with a 
Thl phenotype. It has been described that monocytic y- 
tokines, IL-1 and TNFa, are effector molecules in autoim- 
mune disease [43]. It has also been shown that in the 
course of natural immunization some infectious agents 
expand human T cells with a stable phenotype, ither Thl 
or Th2, as defined by their typical profile of cytokine 
release. This seems to suggest that Thl or Th2 phenotypes 
could represent properties of CD4 ÷ T cells selectively 
elicited by particular antigens [12,13]. Evidence now accu- 
mulating indicates that Th activity is involved in autoim- 
mune diseases. Cytokines produced by Thl cells, such as 
IFNy and IL-2, have been implicated in the exacerbation 
of autoimmune processes. IFNT might favor autoimmunity 
in tissues where the expression of HLA class II molecules 
is induced by this cytokine [21,22]; the possible involve- 
ment of IL-2 in autoimmune diseases has also been de- 
scribed [44]. A Thl cytokine profile is prevalent in organ 
targets of patients with organ specific autoimmune dis- 
eases. The majority of CD4 + cells isolated from thyroid 
infiltrates of patients of Hashimoto's thyroiditis or 
Graves'disease exhibited a Thl phenotype and cytotoxic 
properties. A Thl profile has also been found in CD4 + T 
clones derived from retroorbital infiltrates in patients of 
Graves' ophtalmopathy and the cerebrospinal fluid of pa- 
tients of multiple sclerosis (reviewed in [14]). However, a 
central role of Th2 type cells has been described in the 
pathogenesis of systemic autoimmunity; systemic autoim- 
mune disease can be induced experimentally in rodents 
and this model share several features, such as MHC class 
II hyperexpression B cells, hyper-IgE, increased IL-4 
activity and impairment of IL-2 production [45]. 
We selected also a group of patients whose lym- 
phomononuclear cells spontaneously released amounts of 
cytokines lightly higher than those belonging to healthy 
donors. When cells from patients were incubated in the 
presence of active peptides corresponding to their own 
autoantigens (Figs. 4 and 5) the ensuing release of cy- 
tokines reached a degree higher than that taking place with 
other active peptides, even those related to other autoanti- 
gens. The extent of the response generated by each peptide 
seems to depend on individual genetic factors, since cells 
obtained from patients (all of them with a high risk 
haplotype characteristic of the disease) exhibited a higher 
response to a specific peptide or peptides. This observation 
is not surprising, since, as now widely accepted, each 
MHC haplotype is capable of presenting a large variety of 
peptides, although with specific preferences [15-17]. A 
preference of this type could explain why susceptibility to 
an autoimmune disease is often linked to a particular HLA 
haplotype and/or specific T cell receptors (reviewed in 
[18-20]). 
We suggest that a specific and precise triple interaction 
of HLA-II, peptides of this type and T cells could be 
involved in the pathogenesis of organ specific autoimmune 
diseases. Thus, circulating autoantigens or the protein of 
an infectious agent through molecular mimicry could be 
responsible for the stimulation of autoreactive c lls, which, 
in turn, could cause the priming of autoreactive T-cells. It 
has been demonstrated that autoreactive B and T cells 
specific for autoantigens are components of the normal 
repertoire of lymphocytes [46]. There is also evidence that 
molecular mimicry could cause the disease [47]. A contin- 
uous stimulation of Thl cells by these particular peptides 
having the '2-6-11' motif, and the associated release of 
IFNT, would result in an activation of nonprofessional 
APCs, such as monocytes or tissue cells aberrantly ex- 
pressing HLA-II; it is known that an aberrant expression of 
HLA-II takes place in tissues affected by the autoimmune 
disease a consequence of specific cytokines released by 
Thl cells [21,22]. Once the stimulation of nonprofessional 
APCs has taken place new fragments of autoantigens, 
hidden until that moment, could now be presented (as 
reviewed in [23]). Autoreactive B and T cells, specific for 
'self' 3 structures, would have then their way paved 
towards a potentiation of the autoimmune r sponse and the 
establishment of a state of chronic autoimmunity. 
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